Related Experiment Video

Updated: Feb 24, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

7.2K

Guidelines versus reality: is coronary stent application in three-vessel disease standard or the exception?

Roland Linder1, J Zeidler2, F Verheyen3

  • 1Wissenschaftliches Institut der Techniker Krankenkasse (WINEG), Bramfelder Straße 140, 22305, Hamburg, Germany. prof.dr.roland.linder@wineg.de.

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|August 21, 2017
PubMed

Insights

National guidelines recommend bypass surgery for three-vessel coronary heart disease (CHD). This study found no significant difference in percutaneous coronary intervention (PCI) use, suggesting treatment may not always follow guidelines. Interdisciplinary discussion is advised.

Area of Science:

  • Cardiology
  • Health Services Research

Background:

  • National guidelines recommend coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) for three-vessel coronary heart disease (CHD).
  • Concerns exist regarding adherence to these guidelines in clinical practice for three-vessel CHD.
  • Understanding treatment patterns and factors influencing revascularization decisions is crucial.

Purpose of the Study:

  • To assess adherence to national guidelines for treating patients with one-, two-, and three-vessel coronary heart disease (CHD).
  • To investigate the impact of patient demographics (age, sex) and comorbidities on revascularization strategy selection.
  • To evaluate the utilization of PCI versus CABG in different CHD severity groups.

Main Methods:

  • Analysis of claims data from nearly 10 million patients insured by Techniker Krankenkasse, a major German statutory health insurance fund.
  • Comparison of revascularization rates (PCI vs. CABG) across patient groups with one-, two-, and three-vessel CHD.
  • Statistical analysis to determine the influence of age, sex, and comorbidity on treatment choices.

Main Results:

  • No significant difference in the rate of PCI was observed between patients with one-, two-, or three-vessel CHD.
  • The study could not disprove the hypothesis that patients with three-vessel CHD are not consistently treated according to national guideline recommendations.
  • Patient age, sex, and comorbidity did not significantly alter the observed revascularization patterns in a way that explained guideline deviation.

Conclusions:

  • Current treatment practices for three-vessel coronary heart disease (CHD) may not fully align with national guideline recommendations.
  • The study highlights a potential gap between evidence-based guidelines and actual clinical application for revascularization strategies.
  • Optimal treatment decisions for two- and three-vessel CHD necessitate interdisciplinary collaboration between cardiologists and cardiac surgeons.

Keywords:
Chronic coronary heart diseaseClaims dataCoronary aortic bypass graftingHealth services researchPercutaneous coronary intervention

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.0K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
325
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
321
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
454
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
755
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
345